Full Clinical Guidelines - Community First Health Plans.

More documents

Recommendations

Info

Footnotes 1. American Diabetes Association: Clinical Practice Guidelines 2004. Screening for type 2 diabetes. Diabetes Care. 2004;27(suppl 1):S11-4; Diabetes Care. 2005;28(suppl 1):S4-S36. 2. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97. 3. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9(3):237-52. 4. American Diabetes Association: Clinical Practice Guidelines 2004. The prevention or delay of type 2 diabetes. Diabetes Care. 2004;27(suppl 1):S47-54; Diabetes Care. 2005;28(suppl 1):S4-S36. 5. Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997;46(4):701-10. 6. Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med. 2002;346(11):802-10. Erratum in: N Engl J Med. 2002;346(22):1756. Correction of dosage error in abstract. 7. See Texas Diabetes Council algorithms for treatment of exercise, weight loss, and nutrition. 8. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403 (dose of metformin 850 mg twice daily). 9. No medication is currently FDA-approved for prevention of type 2 diabetes in adults, but a number of studies provide evidence for drug treatment. 10. Metformin is as effective as lifestyle intervention in individuals 35; metformin is nearly ineffective in individuals >age 60 or those with BMI
Publication #45-12000 DIABETIC FOOT SCREEN* * performed every primary care visit (for complete foot exam details, see page 2) Acute swelling and/or Acute deformity ………………. Skin breakdown (ulcer):…………………………….. Callus – with deeper color changes ………………… Digital Deformity ……………………………..….….…. or chronic midfoot/rearfoot prominence History of amputation and/or ulceration ………....……. Dystrophic Nails &/or Dry Skin ……………………. Neuropathy: using 10-gram nylon monofilament performed yearly 4 out of 10 sites imperceptible = “yes” Foot Pulses : Right : Dorsalis Pedis ……………………..… Left : Posterior Tibialis..…………..…… … Dorsalis Pedis …………….……… Posterior Tibialis..…….……….… Palpable NO YES Assign Risk Category: No Present Risk. _____ 0 No loss of protective sensation, no deformity. Impending Risk. _____ 1 No loss of protective sensation. Deformity present. High Risk. _____ 2 Loss of Protective sensation with or without weakness, deformity, callus, pre-ulcer or history of ulceration. Adapted from the National Foot Treatment Center LEAP Program NONpalpable Approved 04-23-04 Page 4-A Page 4-C Page 4-B Page 3-C Page 3 Page 3-D Page 3-B Ankle Brachial Index (ABI)— Page 3-A 9.11 Diabetic Foot Screen, Exam, Care and Referral Resources & References: 1. International Consensus on the Diabetic Foot, 2003. International Working Group on the Diabetic Foot (consultative section of the International Diabetes Federation) 2. University of Texas Health Science Center-San Antonio Texas-Department of Orthopedics-Division of Podiatry 3. Scott & White Clinic / Texas A&M University System Health Science Center-Department of Surgery, Division of Podiatry 4. American Diabetes Association: Clinical Practice Recommendations. Diabetes Care. 2004; 27[S1]:63-64. See web site (http://www.texasdiabetescouncil.org) for latest version and disclaimer. Page 1 H EALTH PLANS www.cfhp.com 65
Page 1 and 2:
Community First Health Plans Qualit
Page 3 and 4:
10.5 ATP III Classification of Chol
Page 5 and 6:
Such information is released only t
Page 7 and 8:
Non Voting • Martin Jimenez, Dire
Page 9 and 10:
The purpose of these guidelines is
Page 11 and 12:
Table 1. Adult Preventive Services
Page 13 and 14: Recommended Adult Immunization Sche
Page 15 and 16: Footnotes — Recommended Adult Imm
Page 17 and 18: CFHP has adopted the National Asthm
Page 19 and 20: Patient Name ______________________
Page 21 and 22: Managing Asthma Long Term 41 FIGURE
Page 23 and 24: FIGURE 14. CLASSIFYING ASTHMA SEVER
Page 25 and 26: FIGURE 16. STEPWISE APPROACH FOR MA
Page 27 and 28: FIGURE 20. CLASSIFYING SEVERITY OF
Page 29 and 30: II. Some hyperactive-impulsive or i
Page 31 and 32: COMMUNITY FIRST HEALTH PLANS BEHAVI
Page 33 and 34: Criteria Requirements 33. Release o
Page 35 and 36: The evaluation of breast disease is
Page 37 and 38: Prevent Child Texas, a non-profit o
Page 39 and 40: AMERICAN ACADEMY OF PEDIATRICS: Fai
Page 41 and 42: possible), a careful, complete, and
Page 43 and 44: Examination/Test Oral / Dental Insp
Page 45 and 46: GLYCEMIC CONTROL BIBLIOGRAPHY • R
Page 47 and 48: Publication # 45-11647 Targets* A1
Page 49 and 50: WORKSHEET Revised 10-20-05 Advancin
Page 51 and 52: D. Optimizing analog insulin use Re
Page 53 and 54: Publication # 45-11266 Age 126 mg/d
Page 55 and 56: Hypertension Algorithm for Diabetes
Page 57 and 58: Lipid Algorithm For Type 1 and Type
Page 59 and 60: References: Revised 1-24-08 • Col
Page 61 and 62: WEIGHT LOSS ALGORITHM FOR OVERWEIGH
Page 63: Publication #45-11825 Screening 1 :
Page 67 and 68: DIABETIC FOOT CARE/REFERRAL ALGORIT
Page 69 and 70: Publication # 45-12083 WEIGHT MANAG
Page 71 and 72: 9 H EALTH PLANS www.cfhp.com 71
Page 73 and 74: Revised 10-25-07 IV INSULIN INFUSIO
Page 75 and 76: Revised 10-25-07 Publication #: 45-
Page 77 and 78: Revised 2-21-08 Publication #: E45-
Page 79 and 80: Abbreviations AGI Alpha-Glucosidase
Page 81 and 82: Orders for Adults with DKA and Hype
Page 83 and 84: D i a b e t e s t r e a t m e n t a
Page 85 and 86: CFHP has adopted the National Insti
Page 87 and 88: No CHD; 0 to 1, or 2+ Risk Factors
Page 89 and 90: NATIONAL CHOLESTEROL EDUCATION PROG
Page 91 and 92: NATIONAL CHOLESTEROL EDUCATION PROG
Page 93 and 94: Identification, Evaluation, and Tre
Page 95 and 96: 11.3 Treatment of Hypertension H EA
Page 97 and 98: ALGORITHM FOR TREATMENT OF MAJOR DE
Page 99 and 100: CFHP has established guidelines for
Page 101 and 102: A. Documentation ______ B. Continui
Page 103 and 104: CFHP PCP MEDICAL RECORD REVIEW TOOL
Page 105 and 106: 13.3 Specialist Medical Record Docu
Page 107 and 108: 13.4 Specialist Medical Record Revi
Page 109 and 110: Risk Factors for Osteoporosis Fract
Page 111 and 112: It is well documented that obesity
Page 113 and 114: CLASSIFICATION OF OVERWEIGHT AND OB
Page 115 and 116:
16.1.1 Preventive Pediatric Health
Page 117 and 118:
H EALTH PLANS www.cfhp.com 117
Page 119 and 120:
TEXAS MEDICAID PROVIDER PROCEDURES
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
CHILDREN’S SERVICES HANDBOOK P h
Page 127 and 128:
CHILDREN’S SERVICES HANDBOOK P R
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
H EALTH PLANS www.cfhp.com 139
Page 141 and 142:
FIGURE 2: Recommended immunization
Page 143 and 144:
Comprehensive antepartum care is vi
Page 145 and 146:
The following variables should be e
Page 147 and 148:
CRITERIA 19. Unresolved Problems Fr
Page 149 and 150:
CFHP OB/GYN SPECIALTY MEDICAL RECOR
Page 151 and 152:
CFHP OB/GYN SPECIALTY MEDICAL RECOR
Page 153 and 154:
According to the National Institute
Page 155 and 156:
. aminotransferase (AST) and alanin
Page 157 and 158:
PREVENTION RECOMMENDATIONS 1. The E
Page 159 and 160:
2 to 20 years: Boys Body mass index
Page 161 and 162:
AsthmaMatters is an initiative deve
Page 163 and 164:
According to the Centers for Diseas
show all

Full Clinical Guidelines - Community First Health Plans.

Create successful ePaper yourself

Delete template?

Save as template?